Skip to Content
  • Revenues ($M)$9,256
  • Revenue Percent Change20.7%
  • Profits ($M)$1,602
  • Profits Percent Change-19.9%
  • Assets ($M)$27,053
  • Employees6,971
  • Market Value — as of March 31, 2016 ($M)$78,237
  • Previous Rank369
  • Morning Consult Brand Index

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Mark J. Alles
Health Care
HQ Location
Summit, NJ
Years on Fortune 500 List5

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$9,25620.7%
Profits ($M)$1,602-19.9%
Assets ($M)$27,053-
Total Stockholder Equity ($M)$5,919-
Market Value — as of March 31, 2016 ($M)$78,237-

Profit Ratios

Profit as % of Revenues17.3%
Profits as % of Assets5.9%
Profits as % of Stockholder Equity27.1%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.94
EPS % Change (from 2014)-18.8%
EPS % Change (5 year annual rate)15.6%
EPS % Change (10 year annual rate)35.9%

Total Return

Total Return to Investors (2015)7.1%
Total Return to Investors (5 year, annualized)32.3%
Total Return to Investors (10 year, annualized)22.1%